N&WICS - TA225 - Golimumab in combination with methotrexate - Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate ore providing patient identifiable data on this form, please confirm that the patient (or in the case of a minor or vulnerable adult with the ent/legal guardian/carer) has given appropriate explicit consent for sensitive personal information on this form to be passed to the CCG and

parent/legal guardian/carer) has giv CSU for processing this funding red	ren appropriate explicit consen	t for sensitive personal inform	ation on this form		
If there is more than one NICE-app about the advantages and disadvar patient is likely to adhere to treatm and price per dose) unless an order	ntages of the treatments availa ent. The most appropriate, lea	ble. This has taken into considest expensive, will be chosen (deration therapeu	tic need and wheth	ner or not the
Patient NHS No:	Trust:		Practice Name:		
Patient Hospital No:	Consultant Making Request:		Practice Postcode:		
Patient's Initials and DoB:			Practice Code:		
Notification Email Address:	(@NHS.ne	et account ONLY)	Contact name & number:		
Start date of requested treatment:		te □NHS ecare □Hospital	Sub-Type:	/A 🔽	
By completing this form, you confir commissioning statement. Any req For support regarding IFRs, please For support regarding the criteria li	uests which fall outside of this contact: norfolkicd@nhs.net	use will require an individual l			ai
Please indicate whether patie	ent meets the following NIC	E criteria:		Please tick	
1. This recommendation has been replaced by the recommendations in the NICE technology appraisal guidance on adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed.				☐Yes ☐No	
2. Golimumab in combination with methotrexate is recommended as an option for the treatment of rheumatoid arthritis in adults whose rheumatoid arthritis has responded inadequately to other DMARDs, including a TNF inhibitor, if:				☐Yes ☐No	
3. When using the disease activity score (DAS28), healthcare professionals should take into account any physical, sensory or learning disabilities, communication difficulties, or disease characteristics that could adversely affect patient assessment and make any adjustments they consider appropriate.					
As per NICE guidance, treatment the dose required, price per dos		·	g (considering		
Please confirm that the choice of drug is considered the most cost-effective treatment for this individual patient, noting that alternative treatment options recommended by NICE may be lower in cost, including the use of biosimilar medications if applicable.				□Yes □No	
Where an alternative lower cost that the clinical rationale for presauditing.					
I confirm that the patient mee	ts the criteria for treatment				
Name of person completing:		Contact Details:			
Designation of person completing	7.	Date:			

Trust Authorising Pharmacist	
Name:	
Date:	